Dr Reddy's Labs

Dr Reddy’s Laboratories, cancer drug, Keytruda, partnership, Alvotech, biosimilar, license agreement, manufacturing

Dr Reddy’s may cut workforce by 25%, including those in Rs 1 crore bracket: Report

Dr Reddy’s may cut 25% of its workforce, including high earners, amid cost-cutting. Learn more!

Updated: April 14, 2025 20:12 IST

Three reasons why pharma stocks are falling today?

Pharma stocks are under significant selling pressure. Here is a detailed analysis on the top worries for the sector.

Updated: March 25, 2025 14:45 IST

Share price of Dr Reddys Lab today, January 24

Jefferies, Nuvama cut target price for Dr Reddy’s. 3 thing to know…

Dr Reddy’s share prices dropped today as brokerages cut targets due to weak US and India performance. Explore the financial…

January 24, 2025 09:17 IST

Satish Reddy, who is Satish Reddy, Satish Reddy net worth, Dr. Reddy’s Laboratories, Dr. Reddy’s Laboratories revenue, lifestyle

Meet the second-generation dynamo: Satish Reddy’s astounding leadership at the helm of a Rs 93,763 crore Pharma giant

Satish Reddy, the dynamic chairman of Dr. Reddy’s Laboratories, stands as a testament to the prowess of the second generation…

Updated: December 27, 2023 12:48 IST

Dr Reddy’s Labs stock– short-term tech pick: further rise anticipated; check best price to buy, stop loss level

Prabhudas Lilladher’s report recommended investors to buy the Dr Reddy’s Laboratories shares with a target price of Rs 6,000, 9.25%…

October 10, 2023 10:45 IST

Dr Reddy’s Labs stock makes new all-time high today after Andhra Pradesh facility clears US FDA inspection

Dr Reddy’s Laboratories made a new 52-week high today after USFDA completed PAI and a routine GMP inspection at the…

Updated: July 20, 2023 11:37 IST

Dr Reddy’s Laboratories, Q2FY24 results, pharmaceutical, revenue, profit, EBITDA, capital expenditure, R&D investments, cash flow, Generics business, new products, Pharmaceutical Services and Active ingredients, price erosion

Dr Reddy’s Labs share price outlook: Weak Revlimid sales to hurt as pharma grows; Check brokerage calls, target

Dr Reddy’s Laboratories share price plunged nearly 7% on Thursday after the pharma major posted a lower-than-expected EBITDA, net profit…

Updated: May 11, 2023 14:20 IST

Novartis, Heart failure, patent expiry, Indian cardiac market, healthcare news, pharma news,

Some Biosimilar products help in increasing neutrophil counts of cancer patients, which helps to boost the immune system and reduce…

December 18, 2022 20:41 IST

Dr. Reddy's, Dr Reddy's labs, Difluprednate Ophthalmic Emulsion, eye drops, eye care, health news, pharma news,

Dr. Reddy’s Hyderabad factory gets recognition from World Economic Forum

According to WEF, the global manufacturing community is lagging behind in its adoption of Fourth Industrial Revolution technologies.

October 11, 2022 13:15 IST

Dr. Reddy’s Laboratories enters into licensing pact with Slayback Pharma

Lumify is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye…

August 1, 2022 12:47 IST

Dr Reddy, Dr Reddy labs, Q1 results, healthcare, pharma news,

Other income pushes Dr Reddy’s PAT up 108% at Rs 1188 Cr in Q1

Revenues during the quarter under discussion were up by six per cent to Rs 5215.4 crore compared to Rs 4,919.4…

July 28, 2022 18:45 IST

Dr. Reddys, Dr Reddys laboratories, Bortezomib, health news, pharma news,

Dr. Reddy’s Laboratories launches Bortezomib for Injection in US

Meanwhile, Dr. Reddy’s Bortezomib for Injection is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous…

Updated: July 27, 2022 21:15 IST

Dr Reddys, Dr Reddy labs, health news, pharma news,

Dr Reddy’s sets its goal to triple its reach to 1.5 billion patients by 2030

The company also said it will have three innovative products improving the standard of treatment every year. On carbon emissions,…

July 7, 2022 20:24 IST

Dr Reddy’s shares may rally 27% on double-digit growth; Sharekhan says buy, check target price

Dr Reddy’s Q4FY2022 performance is expected to be weak, given the elevated cost pressures leading to expected margin contraction. Adverse…

April 15, 2022 15:09 IST

Its consolidated revenue during July-September 2021 stood at Rs 5,763.2 crore. It was Rs 4,896.7 crore in the year-ago period, it added.

Dr Reddy’s Q4 profit dips 29 pc to Rs 557 cr

Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in…

May 14, 2021 14:57 IST

Dr Reddy’s Laboratories rating – Buy: API supplies for Vascepa are an issue

Gradual ramp-up of drug expected through FY22, with US revenues of $25 m; FY22e EPS down 1%; ‘Buy’ retained with…

March 16, 2021 02:45 IST

Dr Reddy's Laboratories, Dr Reddy's, Dr Reddy's share price, Dr Reddy's XenoPort, XenoPort, XenoPort Dr Reddy's, business news

Dr Reddy’s Labs Q4 consolidated net profit dips 85% at Rs 74.60 crore

For the financial year ended March 2016, the company reported net profit of Rs 2,001.30 crore, down 9.76 per cent,…

Updated: May 13, 2016 10:32 IST

Dr Reddy’s Labs shares surge on buyback approval

Dr Reddy’s Laboratories shares surged as much as 4 per cent on Wednesday after the pharma company approved buyback of…

Updated: February 17, 2016 17:22 IST

Related News

Asia Cup Trophy Controversy: India refuses award, PCB proposes special handover

Asia Cup 2025 Trophy row: PCB chief Mohsin Naqvi sends firm message to BCCI, says ‘If you want the trophy, we…’

Four big companies have now stopped sponsoring H-1B visas. Here is the full list

Aadhaar rule change 2025: New UIDAI update fees, PAN-Aadhaar link and KYC rules explained

Big Aadhaar update from November 2025: No document upload needed — UIDAI to verify details automatically

India agrees to cut Russian oil imports, US may slash tariffs to 15% under new trade deal: Report

India agrees to cut Russian oil purchase, open agriculture- Trump may reduce tariff to 15%: Report

Techie discusses move back to India amid Green Card concerns.

Techie plans return to India after 15 years in US amid green card uncertainty, says ‘want to move before…’

Markets muted: Nifty struggling below 25,900, Sensex down 100 points; Cipla down 3%

Market33 min ago

Indian equity benchmarks, Sensex and Nifty, started Friday’s session with a slight decline. The Nifty Bank index also opened higher. Traders are eyeing Nifty’s record high and are hopeful for US tariff cuts on Indian imports. However, oil prices, US-China trade tensions, and FIIs turning net sellers could cap the upside.

View all shorts